Carvedilol Plus Endoscopic Cyanoacrylate Injection Versus Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding
Phase: PHASE4
Conditions: Esophageal and Gastric Varices
Sponsor: Kaohsiung Veterans General Hospital.

1 
 
Carvedilol as an adjunct to endoscopic cyanoacrylate injection for secondary 
prophylaxis of gastric variceal bleeding 
 
Protocol ID: VGHKS11-CT10-11 
ClinicalTrials.gov ID: NCT02504723 
 
Principle investigator: Wen-Chi Chen, MD 
Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
Kaohsiung Veterans General Hospital, 
No. 386, Ta-Chung 1st. Rd., Kaohsiung City 813, Taiwan 
Tel: +886-7-3422121 ext. 2075; Fax: 886-7-3468237; Email: wcchen@vghks.gov.tw 
 
Document date: Dec. 12, 2011 

2 
 
Materials and methods 
Patients 
Cirrhotic patients presenting with acute GVB were evaluated for eligibility.  
The inclusion criteria were:  
(1) age of 20 to 80 years;  
(2) cirrhotic patients with acute GVB proven by endoscopy within 24 h of bleeding; 
(3) stable hemodynamic condition for at least 3 days after a cyanoacrylate injection. 
The exclusion criteria were:  
(1) previous treatment for gastric varices (GV), including endoscopic therapy, 
transjugular intrahepatic porto-systemic shunt (TIPSS), or shunt surgery;  
(2) contraindications to NSBBs or cyanoacrylate injection;  
(3) serum total bilirubin > 10 mg/dL;  
(4) grade III/IV hepatic encephalopathy;  
(5) hepatorenal syndrome;  
(6) severe heart failure (NYHA Fc III/IV);  
(7) chronic kidney disease under renal replacement therapy;  
(8) refractory ascites;  
(9) malignancy other than hepatocellular carcinoma;  
(10) pregnancy;  

3 
 
(11) the use of a pacemaker;  
(12) refusal to participate. 
Randomization was performed when the hemodynamic conditions were stable, 
usually 3 to 5 days after initial GVO for acute bleeding. A computer-generated 
randomization sequence in a 1:1 ratio was used for randomization. The randomization 
sequences were concealed until after the patients had given consent to participate in 
the study and the interventions had been assigned.  
The patients randomized to group A underwent repeated GVO until the varices 
were completely obturated. The patients randomized to group B received carvedilol in 
addition to repeated GVO. 
General management 
  Patients were resuscitated with red cells and crystalloid solution. Terlipressin 1 g 
q6h for 3 days was immediately started on arrival at the emergency room. 
Prophylactic antibiotics were administered for 5 days and were adjusted according to 
sensitivity tests in the patients proven to have an infection. After GVO, esomeprazole 
40 mg intravenous infusion twice daily was administrated for 2 days, and then shifted 
to oral esomeprazole 40 mg daily until the ulcers associated with GVO had 
completely healed. 
Endoscopic therapy 

4 
 
The patients underwent emergency GVO whenever possible, usually 4 to 12 hours 
after presentation. GVO was performed using an XQ-260 or H-260 endoscope 
(Olympus Optical Co. Ltd., Tokyo, Japan) and a 22-gauge disposable injection needle 
(EIS 01943, Top Co., Tokyo, Japan) with a mixture of N-butyl-2-cyanoacrylate 
(Histoacryl blue, Braun, Melsungen, Germany) and lipiodol (Guerbet Laboratory, 
Aulnay-Sous-Bris, France) in a 1:1 ratio. The maximum amount of 
N-butyl-2-cyanoacrylate injected was usually 2 mL per session. GVO was performed 
at 3- to 4-week intervals during follow-up endoscopy, with the aim of eradicating the 
GV. GV was considered to be complete obturated when a firm consistency of the 
injected GV was noted in probing with the tip of the injection needle. The patients 
then underwent endoscopic ultrasonography to evaluate the status of obturation if scar 
tissue could not be differentiated from patent GV as previously described.1 The total 
amount of N-butyl-2-cyanoacrylate and the number of treatment sessions required to 
obliterate the GV were recorded. The patients underwent follow-up endoscopy at 
6-month intervals after obturation of GV. GVO was performed if recurrent GVB was 
encountered or GV recurred. Banding ligation was performed using Saeed® 
multi-band ligators (Cook Medical, Bloomington, IN) or Speedband Superview Super 
7™ multiple band ligators (Boston Scientific, Marlborough, MA) for primary or 
secondary prophylaxis of EVB in patients with high-risk EV if they agreed. 

5 
 
Carvedilol administration 
Carvedilol was started immediately after randomization in the patients assigned to 
group B at a dose of 6.25 mg daily. Patients underwent dose escalation every 3 days 
during the admission or every 7 days in the out-patient clinics until the maximum 
tolerated dose was achieved or up to 25 mg daily, with the goal of reducing the resting 
pulse rate by 25% but not less than 55 bpm while the systolic blood pressure was 
greater than 90 mm Hg. Adherence to the regimen was carefully assessed at each 
follow-up visit by questioning the patient and his or her relatives and counting the 
tablets where possible. 
Management of rebleeding 
The patients with recurrent GVB underwent emergency GVO. Emergency 
banding ligation was performed in the patients with EVB. The patients with 
uncontrolled variceal bleeding underwent TIPSS unless otherwise contraindicated. 
 
Study end-points 
The primary end-point of this trial was the occurrence of recurrent GVB. The 
secondary end-points were recurrent upper gastrointestinal bleeding, mortality or liver 
transplantation, and adverse events associated with both therapies. 
 

6 
 
Statistical analysis 
The proposed sample size was 60 cases in each group. 
Demographic data were compared between both groups. Categorical data were 
compared using the chi-square test or Fisher’s exact test as appropriate. Continuous 
variables with normal distribution were compared using independent Student’s t-tests, 
and continuous variables without normal distribution were compared using the 
Mann-Whitney U test. Kaplan-Meier analysis was conducted to examine the time 
from enrollment to the recurrence of GVB, UGIB, and mortality. A log-rank test was 
used to examine variations between groups. Univariate and multi-variate analyses 
using Cox’s proportional hazards model were used to examine the risk factors 
associated with recurrent GVB, UGIB, and mortality. Significance was defined as 
p<0.05 for all two-tailed tests.  
 
 
 

7 
 
References 
1. 
Ryan BM, Stockbrugger RW, Ryan JM. A pathophysiologic, gastroenterologic, 
and radiologic approach to the management of gastric varices. Gastroenterology 
2004;126:1175-89. 
2. 
Rios Castellanos E, Seron P, Gisbert JP, et al. Endoscopic injection of 
cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric 
varices in people with portal hypertension. Cochrane Database Syst Rev 
2015;5:CD010180. 
3. 
Sarin SK, Lahoti D, Saxena SP, et al. Prevalence, classification and natural 
history of gastric varices: a long-term follow-up study in 568 portal hypertension 
patients. Hepatology 1992;16:1343-9. 
4. 
Tan PC, Hou MC, Lin HC, et al. A randomized trial of endoscopic treatment of 
acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band 
ligation. Hepatology 2006;43:690-7. 
5. 
Lo GH, Lai KH, Cheng JS, et al. A prospective, randomized trial of butyl 
cyanoacrylate injection versus band ligation in the management of bleeding gastric 
varices. Hepatology 2001;33:1060-4. 
6. 
Garcia-Pagan JC, Barrufet M, Cardenas A, et al. Management of gastric varices. 
Clin Gastroenterol Hepatol 2014;12:919-28 e1; quiz e51-2. 

8 
 
7. 
Gonzalez R, Zamora J, Gomez-Camarero J, et al. Meta-analysis: Combination 
endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern 
Med 2008;149:109-22. 
8. 
Mishra SR, Chander Sharma B, Kumar A, et al. Endoscopic cyanoacrylate 
injection versus beta-blocker for secondary prophylaxis of gastric variceal bleed: a 
randomised controlled trial. Gut 2010;59:729-35. 
9. 
Hung HH, Chang CJ, Hou MC, et al. Efficacy of non-selective beta-blockers as 
adjunct to endoscopic prophylactic treatment for gastric variceal bleeding: a 
randomized controlled trial. J Hepatol 2012;56:1025-32. 
10. Banares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term 
carvedilol and propranolol administration in the treatment of portal hypertension in 
cirrhosis. Hepatology 2002;36:1367-73. 
11. Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology 
2010;51:2214-8. 
12. Stanley AJ, Dickson S, Hayes PC, et al. Multicentre randomised controlled study 
comparing carvedilol with variceal band ligation in the prevention of variceal 
rebleeding. J Hepatol 2014;61:1014-9. 
13. Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of 
variceal bleeding in cirrhotic patients with haemodynamic non-response to 

9 
 
propranolol. Gut 2013;62:1634-41. 
14. Shah HA, Azam Z, Rauf J, et al. Carvedilol vs. esophageal variceal band ligation 
in the primary prophylaxis of variceal hemorrhage: a multicentre randomized 
controlled trial. J Hepatol 2014;60:757-64. 
15. Bosch J. Carvedilol for preventing recurrent variceal bleeding: waiting for 
convincing evidence. Hepatology 2013;57:1665-7. 
16. Hashizume M, Kitano S, Yamaga H, et al. Endoscopic classification of gastric 
varices. Gastrointest Endosc 1990;36:276-80. 
17. Beppu K, Inokuchi K, Koyanagi N, et al. Prediction of variceal hemorrhage by 
esophageal endoscopy. Gastrointest Endosc 1981;27:213-8. 
18. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in 
patients with end-stage liver disease. Hepatology 2001;33:464-70. 
19. de la Pena J, Brullet E, Sanchez-Hernandez E, et al. Variceal ligation plus 
nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter 
trial. Hepatology 2005;41:572-8. 
20. Lo GH, Chen WC, Wang HM, et al. Randomized, controlled trial of carvedilol 
versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. J 
Gastroenterol Hepatol 2012;27:1681-7. 
21. Banares R, Moitinho E, Piqueras B, et al. Carvedilol, a new nonselective 

10 
 
beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal 
hypotensive effect than propranolol in patients with cirrhosis. Hepatology 
1999;30:79-83. 
22. Bosch J. Carvedilol: the beta-blocker of choice for portal hypertension? Gut 
2013;62:1529-30. 
23. Watanabe K, Kimura K, Matsutani S, et al. Portal hemodynamics in patients with 
gastric varices. A study in 230 patients with esophageal and/or gastric varices using 
portal vein catheterization. Gastroenterology 1988;95:434-40. 
24. Tripathi D, Therapondos G, Jackson E, et al. The role of the transjugular 
intrahepatic portosystemic stent shunt (TIPSS) in the management of bleeding gastric 
varices: clinical and haemodynamic correlations. Gut 2002;51:270-4. 
25. Mishra SR, Sharma BC, Kumar A, et al. Primary prophylaxis of gastric variceal 
bleeding comparing cyanoacrylate injection and beta-blockers: a randomized 
controlled trial. J Hepatol 2011;54:1161-7.